Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera Sciences’ management team are dedicated and focused to making Alimera a leading ophthalmic pharmaceutical company. Our team has demonstrated expertise through the extensive commercialization and development of ophthalmic products. Our strategy behind Alimera is to:
Alimera Sciences’ primary focus is on ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg. ILUVIEN is an intravitreal implant of fluocinolone acetonide that provides treatment of diabetic macular edema for up to 36 months to help patients maintain vision and reduce the number of injections they receive. Through its unique CONTINUOUS MICRODOSING technology, ILUVIEN releases continuous, low-dose corticosteroid therapy with a single injection for up to 36 months.
ILUVIEN has received approval in the United States, Canada and certain Middle Eastern countries for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
ILUVIEN has also been granted marketing authorizations in Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the United Kingdom as “ILUVIEN® 190 micrograms intravitreal implant in applicator”, for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. ILUVIEN is commercially available in Austria, Germany, Ireland, Italy, Portugal, Spain and the United Kingdom.